Open Access
Review
Table 1
- Current regimen of treatment for lung cancer.
| Drug name | Generic name | Use | ||
| Xeloda | Capecitabine | anti-metabolites | ||
| Avastin | Bevacizumab | VEGF/VEGFR inhibitors | ||
| Tarceva | Erlotinib | EGFR inhibitors | ||
| Cytoxan | Cyclophosphamide | alkylating agents | ||
| Taxol | Paclitaxel | mitotic inhibitorsa | ||
| Taxotere | Docetaxel | mitotic inhibitors | ||
| Gemzar | Gemcitabine | antimetabolites | ||
| Erbitux | Cetuximab | EGFR inhibitors | ||
| Alimta | Pemetrexed | antimetabolites | ||
| Navelbine | Vinorelbine | mitotic inhibitors | ||
| Platinol | Cisplatin | alkylating agents | ||
| Trexall | Methotrexate | antimetabolites, antipsoriatics, antirheumatics | ||
| Ethyol | Amifostine | antineoplastic detoxifying agents | ||
| Iressa | Gefitinib | EGFR inhibitor | ||
| Neosar | Cyclophosphamide | alkylating agents | ||
| Platinol-AQ | Cisplatin | alkylating agents | ||
| Photofrin | Porfimer | miscellaneous antineoplastics | ||
| Onxol | Paclitaxel | mitotic inhibitors |